Immunoglobulin for Myasthenia Gravis

Authors: Alzuabi MA.; Manolopoulos, A.; Elmashala, A.; Odabashian, R.; Naddaf, E.; Murad, MH.

Affiliations: Department of Neuroscience, Division of Clinical Neurology, Medical University of South Carolina, Charleston, USA.

Publication: Cochrane Database of Systematic Reviews; 2020 ; April 2021

Abstract: OBJECTIVES This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of immunoglobulin in adults and children with acute exacerbation or worsening of myasthenia gravis (MG), or with chronic stable generalized MG. Specifically, we will investigate: 1) intravenous immunoglobulin (IVIg) compared to subcutaneous immunoglobulin (SCIg), and 2) immunoglobulin administered via either route (irrespective of treatment duration, dosage, and regimen) compared to no treatment, placebo, acetylcholinesterase inhibitors, plasma exchange, corticosteroids, or other immunosuppressive therapy.